Drug Trial Radar · NCT05011019
A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis
Last checked: Nov 19, 2026Latest source record: Mar 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
22
Actual
Start
Sep 7, 2021
Primary completion
Feb 2, 2024
Study completion Feb 2, 2024
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
AL2846 is a multi-target receptor tyrosine kinase inhibitor. The purpose of this study is to evaluate the safety and efficacy of AL2846 capsules in Chinese patients with type I neurofibromatosis (NF1) (neurofibromas and malignant peripheral nerve sheath tumors).
Conditions
- Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors
Interventions
AL2846 capsulesDrug
AL2846 is a multi-target receptor tyrosine kinase inhibitor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse event rateTime frame: :Baseline up to 96 weeks
- objective response rate (ORR)Time frame: Baseline up to 96weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Ninth People's Hospital, School of Medicine, Shanghai JiaoTong University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.